Suggested remit: To appraise the clinical and cost effectiveness of nintedanib within its marketing authorisation for treating interstitial lung disease caused by systemic sclerosis.
Topic is suspended
 
Status Suspended
Process STA 2018
ID number 1420

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 September 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease. For information and following advice received from the company, the appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease [ID1420] has now been suspended. This is because the Scleroderma-associated interstitial lung disease (SSc-ILD) population for ID1420 will now be covered within the licence for the appraisal for nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]. For further information on the timelines for ID1599 please see the following link: https://www.nice.org.uk/guidance/indevelopment/gid-ta10520
01 September 2020 Suspended. Topic is suspended
01 September 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease. For information and following advice received from the company, the appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease [ID1420] has now been suspended. This is because the Scleroderma-associated interstitial lung disease (SSc-ILD) population for ID1420 will now be covered within the licence for the appraisal for nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]. For further information on the timelines for ID1599 please see the following link: https://www.nice.org.uk/guidance/indevelopment/gid-ta10520
20 June 2019 In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease. Please note that following on from advice received from the company, information regarding the timelines for this appraisal will be available in due course.
11 January 2019 (14:30) Scoping workshop (London)
15 November 2018 - 13 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance